Rethinking domestic and international finance for HIV

Antiretroviral drugs are now available in developing countries at a moderate cost. People living with HIV can live almost normal lives if provided with and adhering to treatment. HIV has shifted from a medical issue to a financial issue: in poor and high-prevalence countries, commitments to increase access to antiretroviral treatment create a huge fiscal liability. In this research, I study how domestic and international financing can be used to meet this liability.

Researchers
Olivier Sterck
Junior Research Fellow in the Economics of Forced Migration
Paul Collier
Blavatnik School of Government, University of Oxford
Richard Manning
Blavatnik School of Government, University of Oxford
Funder(s):